Maurie Markman, MD

It is difficult to overstate the excitement surrounding the development of two new effective therapeutic strategies in the management of metastatic melanoma.

A summary of findings from the 43rd Annual Meeting on Women's Cancer with the potential to impact routine management of women with pelvic malignancies.

A recent study suggests patients may be selected for therapy based on the number of EGFR gene copies, and evaluated for clinical benefit based on the severity of the rash that often develops.

Dr. Maurie Markman, from Cancer Treatment Centers of America, on Awareness of Long-Term Chemotherapy Side Effects

The demonstrated impact of imatinib mesylate on outcomes for patients with CML shifted the oncology paradigm to an intensive search for relevant molecular target.

Dr. Maurie Markman, Cancer Treatment Centers of America, on Primary Care Physician Awareness of Long-Term Chemotherapy Side Effects

The long-sought aim of treating malignant disease by targeting particular molecular abnormalities is becoming a reality in an increasing number of clinical settings.

It is always difficult to distinguish what may legitimately be considered disease flare from the more likely scenario of the events simply representing the natural history of the malignancy.

A review of interesting presentations from ASH that will stimulate highly clinically relevant discussion regarding disease management within the realm of the hematologic malignancies.

Patients who initially exhibit a response to a particular strategy may achieve substantial clinical benefit if the same or very similar agents are delivered after variably defined treatment-free intervals.

This commentary will highlight 2 phase III randomized trials and a retrospective review of a large national database that has been strongly criticized based on its overall conclusions.

It is increasingly recognized that the realm of molecular diagnostic testing in oncology is undergoing as much change, if not more, as the world of cancer therapeutics.

Recently reported and truly impressive clinical trial data have revealed the relevance of administering antineoplastic agents specifically and prospectively targeted to molecular abnormalities.

The presence or absence of lymph node involvement has long been recognized as a critically relevant prognostic factor in solid tumor oncology.

Dr. Maurie Markman from Cancer Treatment Centers of America Discusses Diagnostic Molecular Testing

Dr. Maurie Markman from Cancer Treatment Centers of America Discusses the Importance of Diagnostic Testing

One of the more unique aspects of cancer chemotherapy is the relatively frequent development of serious, even severe, adverse effects.

This report highlights 5 abstracts relevant to the current and future management of patients with female pelvic malignancies.

The desire to reduce the risk and severity of treatment-related toxicity by rapidly discontinuing ineffective therapy, and the increasing use of highly sensitive imaging technology.

The oncology community is quite conversant with the clinical utility of prognostic tumor markers.

Which studies should influence how I manage my patients and what criteria should I use to make these decisions?

Abstracts presented at the 2011 ASCO Annual Meeting will have a major impact on both standard-of-care disease management and the future of clinical trials in multiple settings.

Despite the importance of the recently enacted federal healthcare law, a remarkable 50% of the public does not know its current status.

Despite misgivings among physicians, the Internet is growing as a source of health information for patients.

Healthcare professionals in many specialties, particularly oncology, have long wrestled with the complexities and costs of integrating electronic medical records

Dr. Markman on HPV Testing to Detect Cervical Cancer

Dr. Markman Discusses the Swedish PSA Screening

Dr. Markman Discusses the Olaparib Phase II Trial

Dr. Markman Discusses the Importance of Cancer Screening

Dr. Markman on Taxane-Induced Neuropathy Biomarkers